Search

Displaying results 1001 - 1010 of 2454 in total
  1. Drug

    Hydrocortisone valerate

    go.drugbank.com/drugs/DB14544
    ApprovedVet approved

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Inducers
  2. Drug

    Larotrectinib

    go.drugbank.com/drugs/DB14723
    ApprovedInvestigational

    Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell gr...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  3. Drug

    Oliceridine

    go.drugbank.com/drugs/DB14881
    ApprovedInvestigational

    Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors. Opioid receptors are seven-transmembrane G...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  4. Drug

    Mavacamten

    go.drugbank.com/drugs/DB14921
    ApprovedInvestigational

    Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is ...

    Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Substrates
  5. Drug

    Avutometinib

    go.drugbank.com/drugs/DB15254
    ApprovedInvestigational

    Avutometinib is a small molecule kinase inhibitor targeted against RAF/MEK1, key regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. The MAPK pathway is implicated in variety of cancers, playing a key role in tumor cell proliferation, diff...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    Sotorasib

    go.drugbank.com/drugs/DB15569
    ApprovedInvestigational

    Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer. This mutation makes up >50% of all KRAS...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  7. Drug

    Selpercatinib

    go.drugbank.com/drugs/DB15685
    ApprovedInvestigational

    Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although mult...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  8. Drug

    Homochlorcyclizine

    go.drugbank.com/drugs/DB15979
    Investigational

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  9. Drug

    Crinecerfont

    go.drugbank.com/drugs/DB18518
    ApprovedInvestigational

    [A264818] The majority of the poor health outcomes in patients with CAH result from the inability to precisely titrate glucocorticoid dosages to both adequately replace the deficiency and sufficiently

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  10. Drug

    Imlunestrant

    go.drugbank.com/drugs/DB19043
    ApprovedInvestigational

    Imlunestrant is a brain-penetrant selective estrogen receptor antagonist and degrader. The FDA approved imlunestrant on September 25, 2025 as a treatment for estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-muta...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates